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Chloroplast-Derived Vaccine Antigens and Biopharmaceuticals: Expression,
Folding, Assembly and Functionality
Abstract
Chloroplast genetic engineering offers several advantages, including high levels of transgene expression,
transgene containment via maternal inheritance, and multi-gene expression in a single transformation
event. Oral delivery is facilitated by hyperexpression of vaccine antigens against cholera, tetanus, anthrax,
plague, or canine parvovirus (4%–31% of total soluble protein, TSP) in transgenic chloroplasts (leaves) or
non-green plastids (carrots, tomato) as well as the availability of antibiotic free selectable markers or the
ability to excise selectable marker genes. Hyperexpression of several therapeutic proteins, including
human serum albumin (11.1% TSP), somatotropin (7% TSP), interferon-alpha (19% TSP), interferongamma (6% TSP), and antimicrobial peptide (21.5% TSP), facilitates efficient and economic purification.
Also, the presence of chaperones and enzymes in chloroplasts facilitates assembly of complex
multisubunit proteins and correct folding of human blood proteins with proper disulfide bonds.
Functionality of chloroplast-derived vaccine antigens and therapeutic proteins has been demonstrated by
several assays, including the macrophage lysis assay, GM1-ganglioside binding assay, protection of HeLA
cells or human lung carcinoma cells against encephalomyocarditis virus, systemic immune response,
protection against pathogen challenge, and growth or inhibition of cell cultures. Purification of human
proinsulin has been achieved using novel purification strategies (inverse temperature transition property)
that do not require expensive column chromatography techniques. Thus, transgenic chloroplasts are ideal
bioreactors for production of functional human and animal therapeutic proteins in an environmentally
friendly manner.
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Chloroplast genetic engineering offers several advantages, including high levels of transgene
expression, transgene containment via maternal inheritance, and multi-gene expression in a single
transformation event. Oral delivery is facilitated by hyperexpression of vaccine antigens against
cholera, tetanus, anthrax, plague, or canine parvovirus (4%–31% of total soluble protein, TSP) in
transgenic chloroplasts (leaves) or non-green plastids (carrots, tomato) as well as the availability of
antibiotic free selectable markers or the ability to excise selectable marker genes. Hyperexpression
of several therapeutic proteins, including human serum albumin (11.1% TSP), somatotropin (7%
TSP), interferon-alpha (19% TSP), interferon-gamma (6% TSP), and antimicrobial peptide (21.5%
TSP), facilitates efficient and economic purification. Also, the presence of chaperones and enzymes
in chloroplasts facilitates assembly of complex multisubunit proteins and correct folding of human
blood proteins with proper disulfide bonds. Functionality of chloroplast-derived vaccine antigens
and therapeutic proteins has been demonstrated by several assays, including the macrophage lysis
assay, GM1-ganglioside binding assay, protection of HeLA cells or human lung carcinoma cells
against encephalomyocarditis virus, systemic immune response, protection against pathogen
challenge, and growth or inhibition of cell cultures. Purification of human proinsulin has been
achieved using novel purification strategies (inverse temperature transition property) that do not
require expensive column chromatography techniques. Thus, transgenic chloroplasts are ideal
bioreactors for production of functional human and animal therapeutic proteins in an environmentally
friendly manner.
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Introduction
Vaccines and therapeutic proteins are the great successes of modern medicine, which have
been used for several decades to prevent diseases and eradicate them. The uses of vaccines and
therapeutic proteins have great potential but are limited by their cost of production, distribution,
and delivery. Modified mammalian cells are used for producing therapeutic proteins, which
have the advantage of resulting in products that are similar to their natural counterparts. These
cells can be cultured on a limited scale but production is quite expensive. Bacteria can be used
for large-scale production of proteins, but the products differ from the natural products
considerably. For example, the proteins that are usually glycosylated in humans are not
glycosylated by bacteria. Moreover, many proteins are expressed in Escherichia coli on a large
scale, but sometimes they may differ in conformation with eventual precipitation due to a lack
of proper folding and disulfide bridges (Daniell et al. 2001d).
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For ages, humans have been using plants as a source of food, clothing, medicine, and building
materials. Plants have been of immense help in the past and continue to be so. Plants are now
one of the new hosts for the production of biopharmaceuticals, polymers, vaccines, enzymes,
plasma proteins, and antibodies. There are many advantages in production of recombinant
proteins in plants. Primarily, plant systems are more economical in that they can be produced
on a large scale rather than using industrial methods (fermentation of bacteria, yeast or cultured
animal or human cell lines) that are very expensive. Also, there is no need to maintain the cold
chain as the plant parts expressing the vaccine or plant extracts can be stored and transported
at room temperature. Plants have the ability to carry out posttranslational modifications similar
to naturally occurring systems. There is also minimized risk of contamination from potential
human pathogens, as plants are not hosts for human infectious agents (Giddings et al. 2000).
If therapeutic proteins are delivered orally, then the purification step from plants can be
eliminated. Other advantages of foodbased vaccines include the low cost of raw material and
convenient storage; the cost of syringes and needles in delivery of vaccines is eliminated, which
thereby eliminates blood-borne pathogens.

Plant Expression System
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Many different proteins with applications for human or animal vaccines, biopharmaceuticals,
and biopolymers have been expressed in transgenic plants. With a few exceptions, most often
very low expression levels of foreign proteins (less than 1% of the total soluble protein) were
observed in nuclear transgenic plants (Daniell et al. 2001d), including the B subunit of
enterotoxigenic E. coli (0.01% TSP; Haq et al. 1995), hepatitis B virus envelope surface protein
(0.01% TSP; Mason et al. 1992; Thanavala et al. 1995), human cytomegalovirus glycoprotein
B (0.02% TSP; Tackaberry et al. 1999), and transmissible gastroenteritis coronavirus
glycoprotein S (0.06% TSP; Gomez et al. 1998). Also, gene silencing can occur in nuclear
transformation, which results in lower expression of recombinant proteins. For commercial
exploitation of the therapeutic proteins and vaccine antigens, high and reliable levels of
expression are required, which could be achieved by alternative approaches.

Chloroplast Expression System
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The highest level of protein expression of Bacillus thuringiensis (Bt) cry2Aa2 in plants was
achieved at 46.1% TSP in transgenic tobacco chloroplasts (De Cosa et al. 2001). Besides such
high expression levels, there are several other advantages of chloroplast genetic engineering
over nuclear transformation. Chloroplast genomes defy the laws of Mendelian inheritance in
that they are maternally inherited in most crops (Zhang et al. 2003) and thus minimize outcrossing of transgenic pollen with related weeds or crops. Even if the pollen from plants that
exhibit maternal inheritance contains metabolically active plastids, the plastid DNA is lost
during pollen maturation and is not transmitted to the next generation (Daniell 2002).
Therefore, the chloroplast expression system is an environmentally friendly approach. Also,
chloroplasts have the ability to express multiple genes in a single transformation event.
Expression of polycistrons in transgenic chloroplasts is a unique feature, which facilitates the
expression of entire pathways in a single transformation event (De Cosa et al. 2001; Daniell
and Dhingra 2002). For the first time, a complete bacterial operon was successfully expressed
in transgenic chloroplasts, resulting in the formation of stable cry2Aa2 crystals (De Cosa et al.
2001). This should facilitate expression of polyvalent vaccines or multisubunit proteins in
transgenic chloroplasts.
In addition, the position effect seen in nuclear transgenics can be eliminated as the transgenes
are targeted into spacer regions at precise locations in the chloroplast genome by homologous
recombination of chloroplast DNA flanking sequences. The problem of gene silencing has not
been observed in transgenic chloroplasts in spite of higher expression levels than in nuclear
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transgenic plants. It has been observed that there is no gene silencing in spite of high translation
levels, up to 46.1% TSP (De Cosa et al. 2001) or transcription in transgenic chloroplasts, despite
accumulation of transcripts 169-fold and 150-fold higher than nuclear transgenics (Lee et al.
2003; Dhingra et al. 2004).
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Chloroplasts also have the ability to process eukaryotic proteins, including correct folding of
subunits and formation of disulfide bridges (Daniell et al. 2001d). Functional assays showed
that chloroplast-synthesized cholera toxin-B subunit binds to the intestinal membrane GM1ganglioside receptor, thereby confirming the correct folding and disulfide bond formation
(Staub et al. 2000; Daniell et al. 2001b; Molina et al. 2004). Chaperones present in chloroplasts
facilitate correct folding and assembly of monoclonal antibody in transgenic chloroplasts
(Daniell et al. 2004a) and also result in fully functional human therapeutic proteins, as seen in
interferon alpha and gamma (Falconer 2002; Leelavathi and Reddy 2003). Chloroplasts can
be a good place to store the biosynthetic products that could otherwise be harmful when
accumulated in cytosol (Bogorad 2000). This was demonstrated when cholera toxin B subunit
was accumulated in large quantities in transgenic chloroplasts and it had no toxic effect (Daniell
et al. 2001b), whereas when accumulated in the cytosol in very small quantities, CTB was toxic
(Mason et al. 1998). Similarly, trehalose, which is used as a preservative in the pharmaceutical
industry, was toxic when accumulated in cytosol but was nontoxic when compartmentalized
within chloroplasts (Lee et al. 2003). Several therapeutic proteins and vaccine antigens
expressed via the chloroplast genome are listed in Tables 1 and 2.
Novel Purification Strategies
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The main reason for the high cost of pharmaceutical protein production is purification of
recombinant proteins. Therefore, novel protein purification strategies can be used that do not
require the use of expensive column chromatography. For instance, a synthetic protein-based
polymer gene (GVGVP) 121 has been expressed in E. coli and a very high expression level was
achieved such that polymer inclusion bodies were formed that occupied nearly 90% of the cell
volume (Daniell et al. 1997; Guda et al. 2000). (GVGVP) 121 exhibits inverse temperature
transition properties, making it soluble in water below room temperature, but aggregates into
a more ordered, viscoelastic state, called a coacervate, at 37°C (Daniell et al. 1997; Guda et al.
2000). The inverse temperature transition property makes purification easier and less expensive
in aqueous solutions simply by raising the temperature. In addition, this property makes
(GVGVP) 121 an ideal fusion protein for purification. To demonstrate this, the proinsulin gene
was fused to a smaller version of this biopolymer (GVGVP) 40 with inverse temperature
transition properties and was expressed in E. coli (Daniell et al. 2004a). At 4°C, the biopolymer
exists as an extended molecule, but when incubated at 42°C, it folds into dynamic structures
called β-spirals that further aggregate by hydrophobic association to form twisted filaments
(Urry et al. 1996). Therefore, this principle was successfully used to purify the fusion protein
simply by raising the temperature to 42°C and was analyzed on SDS-polyacrylamide gel. The
presence of polymer in the proinsulin-polymer fusion protein was confirmed by negatively
staining the SDS-PAGE gels with 0.3 M Cucl2 (Fig. 1a). Copper stained gels, when illuminated
obliquely, show dark bands against a light, semiopaque background. The same gel was stained
with Coomassie R-250. The sulphonic acid groups in the dye (Coomassie R-250) form ion
pairs with lysine and arginine in the protein, which are not present in the polymer but are present
in proinsulin. Since the Coomassie R-250 stained the polypeptide, it confirms the presence of
fusion protein (Fig. 1b). After purification, the fusion protein can be cleaved with suitable
enzymes and the polymer can be discarded in the pellet fraction by another round of
polymerization at 42°C followed by centrifugation. This novel purification strategy should
significantly decrease the purification cost because of the elimination of column
chromatography.
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Oral delivery of vaccines is an attractive alternative because of the ease of administration and
low costs. Also, oral delivery of the recombinant protein could reduce the production costs by
almost 90%. As pointed out above, chloroplast genetic engineering is most suitable for
hyperexpression of vaccine antigens and therapeutic proteins. However, oral delivery of
vaccine antigens could significantly reduce the cost of their production, purification, storage,
and transportation, thereby eliminating the need to maintain the cold chain. To achieve oral
delivery of vaccines, one of the important requirements is the production of therapeutic proteins
in antibiotic free selection.

NIH-PA Author Manuscript

Most transformation techniques use an antibiotic resistance gene along with the gene of interest
such that only the transgenic lines containing the desired trait are selected. But once the trait
has been established, the antibiotic resistance gene has only one purpose: producing its
products. One major concern is horizontal transfer of the antibiotic resistance genes to other
related or unrelated organisms. However, now chloroplasts can be genetically modified without
the use of antibiotic resistance genes. There are several ways of doing this. For example, the
spinach betaine aldehyde dehydrogenase (BADH) gene has been developed as a selectable
marker to transform the chloroplast genome (Daniell et al. 2001c,e). The toxic betaine aldehyde
(BA) is converted to nontoxic glycine betaine by the chloroplast BADH enzyme. This glycine
betaine also serves as an osmoprotectant and confers salt tolerance (Kumar et al. 2004). The
BADH enzyme is present in only a few plant species that are adapted to salty and dry
environments.
In addition, the selectable marker genes can be removed using short, 174-bp DNA repeats, but
the gene of interest could be retained outside the direct repeats, thereby producing marker-free
plants (Iatham and Day 2000). Another method of eliminating the selectable marker is by
employing a transiently co-integrated vector with a single homologous flank (Klaus et al.
2004). The co-integrates are lost rapidly by recombination when the selection pressure is
removed.
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For oral delivery of vaccines, another important requirement is the expression of the vaccine
antigens in plastids of non-green tissues. For the first time, stable and highly efficient plastid
transformation of carrot using non-green tissues as explants, regenerated via somatic
embryogenesis, has been reported (Kumar et al. 2004). A useful plant trait (salt tolerance) has
been expressed for the first time in a non-solanaceous crop via the chloroplast genome. The
carrotspecific plastid transformation vector pDD-Dc-aadA/BADH was constructed and carrot
callus was bombarded. The bombarded callus was plated on selection medium containing 150
mg/l spectinomycin to obtain spectinomycin-resistant transgenic lines. The BADH enzyme
activity was assayed in crude extracts of protein from both transformed and untransformed
carrot cell cultures. BADH enzyme in the presence of betaine aldehyde converts NAD+ to
NADH and the reaction rate was measured by an increase in absorbance at 340 nm due to the
reduction of NAD+ (Kumar et al. 2004). Crude extracts from transgenic plastids showed higher
levels of BADH activity when compared to untransformed tissue (Fig. 2a). High BADH
activity was observed in leaves, tap roots, and cells in suspension culture but the difference in
activity may be due to variation in plastid genome copy numbers. The high BADH activity in
carrot taproot may be due to a large number of chromoplasts, which is evident by the orange
color (Fig. 2b). Also, the protein expression in carrot cells, root, and shoot was tested using
Western blot analysis (Fig. 2c). These results were consistent with the BADH enzyme activity.
Also, glycine betaine is found in many higher plants, bacteria, and mammalian animals, which
they accumulate under conditions of water or salt stress and acts as an osmoprotectant
(Figueroa-Soto et al. 1999). In plants and bacteria, glycine betaine can build up the cytoplasmic
osmotic strength without preventing any cellular functions. BADH was reported to be present
in porcine kidneys localized in both cortex and medulla (Figueroa-Soto et al. 1999).
Curr Top Microbiol Immunol. Author manuscript; available in PMC 2009 October 20.
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Carrot is a biennial plant with a vegetative phase in the 1st year and the reproductive phase in
the 2nd year. Harvesting the crop containing the transgene at the end of 1st year prevents gene
flow through seeds or pollen because there is no reproductive system. Also, maternal
inheritance of carrot chloroplast genomes adds to the environmentally friendly approach
(Vivek et al. 1999). Somatic embryos of carrot are single-cell-derived and multiply through
recurrent embryogenesis, which provides a uniform source of cell culture and a homogeneous
single source, which is a requirement for the production of human therapeutic proteins. Oral
delivery of therapeutic proteins via edible carrots preserves the structural integrity of the
proteins, as no cooking is needed. Encapsulated embryos, which are viable for many years in
culture, can be used for cryopreservation. Because of all these advantages, carrot can be used
as an ideal system for oral delivery.
Chloroplast Derived Vaccine Antigens
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Cholera Toxin B Antigen—Cholera toxin B subunit (CTB) of Vibrio cholerae, a candidate
vaccine antigen, has been expressed in transgenic chloroplasts, and this resulted in
accumulation of up to 4.1% total soluble protein as functional oligomers (Daniell et al.
2001b). Higher expression levels (up to 31.1% TSP) were obtained when CTB-2L21 fusion
protein was expressed in transgenic chloroplasts (Molina et al. 2004). The difference in the
expression levels of the CTB gene was due to the presence of a ribosome-binding site
(GGAGG, 4.1% TSP) or the 5′ UTR of the psbA gene (31.1% TSP). CTB synthesized from
transgenic chloroplasts in both investigations assembled into functional oligomers and were
antigenically identical to purified native CTB. CTB has the highest affinity to bind with
gangliosides (GM1), which are the natural toxin receptors in the intestinal epithelial cells. The
functionality of CTB was determined by the GM1-ganglioside ELISA binding assay (Fig. 3),
where the plates were coated first with GM1-gangliosides and BSA, which was then plated
with the total soluble protein from the transformed and the untransformed plants and bacterial
CTB. Then the absorbance of the GM1—ganglioside—CTB-antibody complex was measured.
The bacterial CTB and chloroplast-synthesized CTB showed a strong affinity for the GM1—
ganglioside complex, confirming that the antigenic sites necessary for the binding of CTB to
GM1 were conserved. With such high levels of expression of an efficient transmucosal carrier
molecule such as CTB in chloroplasts, fusion proteins can be synthesized and also plant-derived
vaccines can be commercialized.
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Anthrax Protective Vaccine Antigen—The Center for Disease Control (CDC) lists
Bacillus anthracis as a category A agent and estimates the cost of an anthrax attack to exceed
$26 billion per 100,000 exposed individuals (Kaufmann et al. 1997). The present vaccine for
anthrax is produced by cell-free filtrate of toxigenic, nonencapsulated strain of B. anthracis
(Baillie 2001). In addition to the protective antigen (PA), the immunogenic portion, trace
amounts of lethal factor and edema factor are present in the filtrate, which are considered to
be toxic and cause side effects (Ivins et al. 1995; Baillie 2001; Joellenback et al. 2002). The
PA heptamerizes and binds itself to the host cell receptor. This can now bind to lethal factor
or edema factor. When bound to lethal factor, the toxin stimulates the release of
interleukins-1β by macrophages and other cytokines that lead to sudden death. For the above
reasons and also because of the limited supply of the current vaccine, biothrax (formerly
anthrax vaccine adsorbed, or AVA), there is an urgent need for an improved and pure vaccine.
Therefore, the B. anthracis 83-kDa PA was expressed in transgenic tobacco chloroplasts. The
PA gene was cloned into the chloroplast transformation vector (pLD-JW1) along with psbA
regulatory signals to enhance translation. The crude plant extracts contained up to 2.5 mg PA/
g fresh weight (Daniell et al. 2004b). The PA protein as a percentage of total soluble protein
expressed in pLD-JW1 plants was determined for 3 and 5 days of continuous illumination. A
maximum 18.1% and 13.4% PA in the total soluble protein was achieved (Fig. 4). The
maximum levels of expression were observed in mature leaves under continuous illumination.

Curr Top Microbiol Immunol. Author manuscript; available in PMC 2009 October 20.

Chebolu and Daniell

Page 6

NIH-PA Author Manuscript

Also, Western blots were performed using two different detergents in the extraction buffer,
CHAPS and SDS, and both extracted PA equally well. After storage for 2 days at 4°C and −20°
C, the PA in the crude extracts was quite stable. Powdered leaf was stored at −80°C for several
months and then Western blots were performed, showing no noticeable decrease in PA quantity
or functionality. This should facilitate the long-term storage of harvested leaves before PA is
extracted for vaccine production. Trypsin, chymotrypsin, and furin proteolytic sites present in
PA expressed in transgenic chloroplasts were protected in that only PA 83 was observed. The
functionality of the antigen was determined by its ability to internalize the lethal factor and
cause the lysis of cultured macrophage cells, which is termed as the macrophage lysis assay
(Fig. 5). The percentage macrophage viability was determined using the ability of live but not
dead cells to reduce a water-soluble yellow dye, MTT (3-[4,5-dimethylthiazol-2-yl [-2,5diphenyltetrazolium bromide) to an insoluble purple formazan product (Daniell et al. 2004b).
The PA also showed heptamerization and cleaved properly. With an average yield of 172 mg
of PA per plant using the experimental transgenic cultivar grown in greenhouse, 400 million
doses of vaccine (free of contaminants) could be produced per acre. The yield could increase
further by 18-fold when a commercial cultivar is used rather than the experimental cultivar.
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Plague Vaccine Antigen—Yersinia pestis, a Gram-negative bacterium, is the causative
agent of plague and has been listed by Center for Disease Control (CDC 2003) as one of the
six category A biological agents. There are three different forms of plague. Bubonic plague,
the most common form of plague, is caused by infected fleas. When it enters the lymph nodes,
the bacterium causes swelling of the nodes and forms buboes; the other forms are septicemic
plague and pneumatic plague. The current vaccine available is a killed whole subunit vaccine,
which is moderately effective against bubonic plague and ineffective against the other two
forms of the plague (Titball and Williamson 2001). Several subunit vaccines have been
evaluated for immunogenicity against Y. pestis. CaF1 and LcrV are the most effective subunit
vaccines so far against Y. pestis. F1 is a capsular protein located on the surface of the bacterium
with antiphagocytic properties. The V antigen is a component of the Y. pestis type III secretion
system and it may form part of an injectosome. The fusion protein of F1-V expressed in E.
coli has been shown to be safe and immunogenic when mice were challenged with Y. pestis
(Williamson et al., 1997). The fusion protein F1-V was expressed in transgenic chloroplasts
consisting of the F1 antigen fused at its carboxy terminus to the amino terminus of the V antigen.
Western blot and ELISA were performed and samples were collected from plants under
continuous illumination from days 0–5 from young, mature, and old leaves (Fig. 6). The
maximum expression levels were observed in mature leaves, which is as high as 14.8% of the
total soluble protein (Arlen et al. 2008). Further studies need to be done to confirm
immunogenicity. Since Y. pestis is one of the category A biological warfare agents and there
is no proper vaccine, improved vaccine is a high priority.
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Canine Parvovirus VP2 Antigen—Canine parvovirus (CPV) infects dogs and other
Canidae such as wolves, South American dogs, and Asiatic raccoon dogs, producing
hemorrhagic gastroenteritis and myocarditis (CPV vaccination, Cornell University) .The 2L21
synthetic peptide, coupled to KLH carrier protein, was studied extensively and has been shown
to be effective in protecting dogs and minks against parvovirus (Langeveld et al. 1994,1995).
The 2L21 peptide, which confers protection to dogs against virulent canine parvovirus (CPV),
was expressed in tobacco chloroplasts as a fusion protein with cholera toxin B (CTB) and with
the green fluorescent protein (GFP). The maximum levels of protein expression were achieved
with CTB-2L21, 7.49 mg/g fresh weight (equivalent to 31.1% total soluble protein) and with
GFP-2L21, 5.96 mg/g fresh weight (equivalent to 22.6% of total soluble protein, Molina et al.
2004; Fig. 7). The expression levels were also dependent on the age of the plant. Mature plants
accumulated the highest amounts of protein when compared to the young and senescent plants.
This shows the importance of the plant’s harvesting time. Also, the chimeric protein retained
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the pentamerization and G M1-ganglioside-binding properties of the native CTB. When mice
were immunized intraperitoneally with the leaf extracts from CTB-2L21, mice immunized with
CTB-2L21 elicited anti-2L21 antibodies able to recognize VP2 protein from CPV (Fig. 8).
This is the first report of an animal vaccine and viral antigen expressed in transgenic
chloroplasts.
Chloroplast-Derived Therapeutic Proteins
Several human therapeutic proteins that have been expressed in transgenic chloroplasts are
listed in Table 2. The expression levels depend on the site of integration, regulatory elements
used to enhance transcription/translation efficiency, and the stability of the foreign protein.
Genes encoding for proteins as small as 20 amino acids (magainin; DeGray et al. 2001) or as
large as 83 kDa (PA; Daniell et al. 2004b) have been expressed in transgenic chloroplasts. A
few illustrations from the Daniell laboratory are described in the following sections.
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Human Serum Albumin—Human serum albumin (HSA), the most widely used intravenous
protein, is obtained by fractionation of blood serum and accounts for approximately 60% of
the total protein in the blood (Fernández-San Millán et al. 2003). The world needs more than
500 tons annually, representing a market value of more than $1.5 billion. HSA was produced
in a wide variety of microbial systems but no system is commercially feasible yet. Expression
of functional HSA in a transgenic chloroplast expression system is advantageous because of
the inexpensive production costs and absence of human pathogens. This protein was expressed
in transgenic chloroplasts under the translational control of a Shine Dalgarno sequence, 5′
psbA region or the cry2Aa2 UTR. Different expression levels were obtained in transgenic plants
with different regulatory sequences; for example, potted transgenic plants regulated by ShineDalgarno sequence showed 0.02% TSP, while 7.2% and 0.08% TSP HSA was observed in
plants regulated by chloroplast 5′ psbA or heterologous cry2Aa2 UTR, respectively. Expression
in seedlings with Shine-Dalgarno control was 0.8% total protein of HSA, while 1.6% TP was
observed with 5′ psbA control and 5.9% TP under cry2Aa2 UTR control. The low levels of
HSA accumulation in mature plants under the control of SD may be due to excessive proteolytic
degradation and poor rates of translation. As 5′ psbA region is light-regulated, under continuous
light illumination for 50 h, the HSA quantity in mature leaves was maximum: 11.1% of the
total soluble protein (Fernández-San Millán et al. 2003). This is 500-fold greater expression
than the previous reports of nuclear expression.
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HSA was observed to form inclusion bodies in transgenic chloroplasts, thus offering protection
from proteolytic degradation (Fig. 9a—c). Inclusion bodies can easily be separated from the
majority of the cellular proteins by centrifugation, thereby eliminating the need for expensive
affinity columns and chromatographic techniques. Properly folded HSA can be recovered from
the inclusion bodies after denaturation for complete solubilization and in vitro refolding
(Fernández-San Millán et al. 2003).
Human Interferon Alpha—Human interferon (IFNα 2b) is used in the treatment of
malignant carcinoid tumors and was shown to be very effective in the reduction of tumor size.
It has other therapeutic values such as inhibition of viral replication, cell proliferation, and
enhancement of immune response, and recently, in treatment of patients suffering from West
Nile virus infection. At present, IFNα 2b protein is produced in E. coli for commercial use and
also requires in vitro processing and purification. The nuclear expression of this protein also
resulted in very low expression (0.000017% TSP) in tobacco (Elderbaum et al. 1992). This has
altogether made the treatment with interferon very expensive, which on average costs $26,000–
$40,000 per year.
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Recombinant IFNα 2b was expressed in transgenic chloroplasts using the chloroplast
transformation vector integrated with the gene cassette that included IFNα2b gene along with
polyhistidine purification tag and a thrombin cleavage site (Fig. 10). Western blots were
performed to detect the multimers and monomer of IFNα 2b using interferon alpha monoclonal
antibodies and confirm formation of disulfide bonds. Integration of the gene cassette into
chloroplast genome was confirmed by Southern blots. ELISA was performed to quantify the
IFNα 2b protein and expression up to 18.8% of total soluble protein was obtained (Arlen et al.,
2007).
The functionality of IFNα 2b was investigated by its ability to protect HeLa cells against the
cytopathic effect of encephalomyocarditis virus (EMC) and through the identification of
interferon-induced transcripts (Fig. 11). The chloroplast derived IFNα 2b is found to have the
same activity as commercially produced Intron A. The mRNA levels of two genes induced by
IFNα 2b (2′-5′ oligoadenylate synthase and STAT-2) were tested by RT-PCR using primers
specific for each gene. Chloroplast-derived IFNα 2b induced the expression of both genes in
a manner similar to commercial IFNα 2b. This confirms that chloroplast derived IFNα 2b is
as active as commercially produced Intron A.
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Human Insulin-Like Growth Factor-1—Human insulin-like growth factor (IGF-1) has
therapeutic value not only in mediating the growth of muscle and other tissues, but its
therapeutic value is being currently evaluated in diabetes, IGF-I induced neuroprotection, and
in promoting bone healing. The IGF-1 is a naturally occurring single-chain polypeptide with
three disulfide bonds, produced in the liver (Torrado and Carrascosa 2003). When produced
in E. coli, IGF-1 cannot produce the mature form, as disulfide bonds cannot be formed in E.
coli cytoplasm. Since the IGF-1 has codons suitable for the eukaryotic environment, codon
was optimized for chloroplast to increase the levels of expression in transgenic chloroplasts.
PCR and Southern blot analysis confirmed the chloroplast integration of IGF-1 gene. ELISA
was performed to quantify the expression levels of IGF-1 from both native and synthetic genes
in transgenic chloroplasts and the expression levels were as high as 32% of the total soluble
protein (Ruiz 2002; Fig. 12). However, quantification of expression of IGF-1 was complicated
by the ZZ-tag used for purification and levels of expression should be verified using antibodies
that do not cross-react with the ZZ-tag. These observations suggest that unlike bacterial
translational machinery, chloroplast translation machinery may be quite flexible.
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Anti-Microbial Peptide—Anti-microbial peptides (AMPs) are a common component of the
innate defense mechanisms in the animal kingdom, which help to combat pathogens and to
control normal microbial flora. Magainin, secreted from the skin of the African clawed frog
(Xenopus laevis), is a broad-spectrum topical agent, a systemic antibiotic and a wound-healing
and anticancer agent (Zasloff 1987; Jacob and Zasloff 1994; DeGray et al. 2001). Magainin
has affinity for the negatively charged phospholipids in the outer leaflet of the prokaryotic
membrane. A magainin analog, MSI-99, was expressed in transgenic chloroplasts and
expression levels up to 21.5% of total soluble protein were obtained (DeGray et al. 2001;
Daniell et al. 2001a). The effectiveness of the lytic peptide expressed in transgenic chloroplasts
was tested with a multidrug resistant Gram-negative bacterium, Pseudomonas aeruginosa, and
this resulted in 96% growth inhibition of the pathogen (Fig. 13). MSI-99 was most effective
against Pseudomonas syringae requiring only 1 μg/1,000 bacteria based on the study of
minimum inhibitory concentration of MSI-99.
Chloroplast-Derived Human Antibody—Monoclonal antibodies for passive
immunotherapy have been the most widely studied therapeutic proteins produced in transgenic
plants. Though large numbers of therapeutic proteins have been produced in plants, only a few
have entered clinical trials. The anti-Streptococcus mutans secretory antibody for the
prevention of dental caries is the only plant-derived antibody currently in phase II clinical trials
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(Larrick and Thomas 2001). Based on chloroplast’s ability to form fully active and assembled
proteins, a codon-optimized and humanized gene encoding a chimeric monoclonal antibody
(IgA/G, Guy’s 13) under the control of a specific 5′-untranslated region, was used to synthesize
monoclonal antibodies in transgenic chloroplasts. Guy’s 13 was developed to prevent dental
caries, which is caused by Streptococcus mutans (Daniell and Wycoff 2001; Daniell et al.
2001a; Daniell 2004). Integration of the chimeric antibody gene into chloroplast genome was
confirmed by PCR and Southern blot analysis. Western blot analysis showed the expression
of heavy and light chains as well as fully assembled antibody (Fig. 14), suggesting the presence
of chaperones for proper protein folding and enzymes for formation of disulfide bond in
transgenic chloroplasts. However, expression levels should be enhanced further to facilitate
commercialization.

Conclusion
The chloroplast genetic engineering approach is ideal for economical production of vaccine
antigens and biopharmaceuticals in an environmentally friendly manner. The proven
functionality and the high expression levels of vaccine antigens and therapeutic proteins in
transgenic chloroplasts hold the promise for unlimited quantities of production, but the cost of
purification is still prohibitive. This can be overcome by the oral delivery of vaccine antigens
and therapeutic proteins or by using the novel purification strategies described in this review.
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Fig. 1.

a, b Expression and purification of insulin-polymer fusion protein detected in copper- (a) and
Coomassie- (b) stained gels. Two rounds of purification through thermally reversible phase
transition were performed. The same gel was first stained with copper, destained, and restained
with Coomassie R-250. Lane 1: Prestained marker; lane 2: purified extract of polymer-insulin
fusion protein from the chloroplast vector pSBL-OC-40Pris; lane 3: reverse orientation of
fusion protein from pSBL-OC-40Pris; lane 4: purified extract of pLD-OC-40Pris; lane 5:
reverse orientation of pLD-OC-40Pris; lane 6: purified extract of E. coli strain XL-1 blue
containing no plasmid
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Fig. 2.

a—c BADH enzyme activity and BADH expression in control and pDD-Dc-aadA/BADH lines.
a BADH activity in untransformed (U) and transformed (T) cell suspension, root and leaf. b
A pDD-Dc-aadA/BADH transgenic line shown with taproot and shoot. c Western blot using
polyclonal anti-BADH serum. Antigenic peptides were detected using horseradish peroxidaselinked secondary antibody. Lanes 1, 2, 3, untransformed cell culture, root and leaf and lanes
4, 5, 6, transformed cell culture, root and leaf
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CTB-GM1-ganglioside binding ELISA assay. Plates, coated first with GM1-ganglioside and
bovine serum albumin (BSA), respectively, were irrigated with total soluble plant protein from
chloroplast transgenic lines (3, 7) and 300 ng of purified bacterial CTB. The absorbance of the
GM1-ganglioside-CTB-antibody complex in each case was measured at 405 nm. Total soluble
protein from untransformed plants was used as the negative control
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Fig. 4.

Quantification of anthrax protective antigen in JW1 plants of T1 generation using ELISA.
Histogram of percentage of PA in the total soluble protein in fresh tissue of young, mature,
and old leaves of plant in 16 h light and 8 h dark (day 0), 3-day continuous illumination and
5-day continuous illumination
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Macrophage cytotoxic assays for extracts from transgenic plants. Supernatant samples from
T1 pLD-JW1 tested (proteins extracted in buffer containing no detergent and MTT added after
5 h). pLD-JW1 (extract stored 2 days); pLD-JW1 (extract stored 7 days); PA 5 μg/ml; control
wild type (extract stored 2 days); control wild type (extract stored 7 days); control wild type
no LF (extract stored 2 days); control wild type no LF (extract stored 7 days); control pLDJW1 no LF (extract stored 2 days); control pLD-JW1 no LF (extract stored 7 days)

NIH-PA Author Manuscript
Curr Top Microbiol Immunol. Author manuscript; available in PMC 2009 October 20.

Chebolu and Daniell

Page 18

NIH-PA Author Manuscript
Fig. 6.

NIH-PA Author Manuscript

Enzyme linked immunoassays expressed, with protein yields expressed as % TSP and
micrograms of F1 V per gram of fresh leaf material. For the continuous illumination
experiment, leaf material was sampled on days 0, 1, 3, and 5. Young, mature, and old samples
were taken for each experiment. The figure shows average levels of F1 V antigen for samples
1–4 [day 0: (1) young, (2) mature, (3) old, and (4) wild-type leaf samples]; samples 5–8 [day
1: (5) young, (6) mature, (7) old and (8) wild-type leaf samples]; samples 9–12 [day 3: (9)
young, (10) mature, (11) old and (12) wild-type leaf samples]; samples 13–16 [day 5: (13)
young, (14) mature, (15) old, (16) wild-type leaf samples]
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Fig. 7.

Coomassie blue-stained sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDSPAGE) gel of plant samples, 60 days after transplanting. Two independent lines (1, 2) for each
construction were analyzed. Recombinant proteins GFP-2L21 and CTB-2L21 are marked.
Fifty micrograms of plant total protein was loaded per well. 2L21 epitope from the VP2 protein
of the canine parvovirus, CTB cholera toxin B, GFP green fluorescent protein, MW molecular
weight marker, WT wild-type Petit Havana plant
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Fig. 8.

Titers of antibodies at day 50 induced by plant-derived CTB-2L21 recombinant protein. Balb/
c mice were intraperitoneally immunized with leaf extract from CTB-2L21 transgenic plants.
Animals were boosted at days 21 and 35. Each mouse received 20 μg of CTB-2L21 recombinant
protein. Individual mice sera were titrated against 2L21 synthetic peptide, VP2 protein and
control peptide (amino acids 122–135 of hepatitis B virus surface antigen). Titers were
expressed as the highest serum dilution to yield twice the absorbance mean of preimmune sera.
M1—M6 mouse 1–6, 2L21 epitope from the VP2 protein of the canine parvovirus, CTB cholera
toxin B, VP2 protein of the canine parvovirus that includes the 2L21 epitope
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Fig. 9.

a—c Study of HSA accumulation in transgenic chloroplasts (a—c) Electron micrographs of
immunogold labelled tissues from untransformed (a) and transformed mature leaves with the
chloroplast vector pLDApsbAHSA (b, c). Magnifications: A×10,000; B×5,000; C×6,300
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Fig. 10.

Coomassie-stained SDS-polyacrylamide gel showing chloroplast transgenic lines expressing
IFN α 2b. Lanes 1 and 2: total soluble protein; lanes PH, 3 and 4: total protein
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Demonstration of IFNα 2b functionality by the ability of IFNα 2b to protect HeLa cells against
the cytopathic effect of encephalomyocarditis virus. Note that chloroplast derived IFNα 2b is
as active as commercially produced Intron A
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Fig. 12.

Expression of IGF-1 in transgenic chloroplasts after continuous illumination for 13 days. IGF-1
expression is shown as a percentage of total soluble protein. IGF-1n is the native gene and
IGF-1 s is the chloroplast codon-optimized gene
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In vitro bioassay for T1 generation chloroplast transgenic line against P. aeruginosa. Bacterial
cells from an overnight culture were diluted to A600 0.1–0.3 and incubated for 2 h at 25°C with
100 μ g of total protein extract. Of LB, 1 ml was added to each sample and incubated overnight
at 26°C. Absorbance was recorded at 600 nm. Data were analyzed using Graph Pad Prism
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Western blot analysis of transgenic lines showing the expression of an assembled Guy’s 13
monoclonal antibody in transgenic chloroplasts. Lane 1: extract from a chloroplast transgenic
line; lane 2: extract from an untransformed plant; lane 3: positive control (human IgA). The
gel was run under nonreducing conditions. The antibody was detected with AP-conjugated
goat anti-human kappa antibody
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CtxB
TetC (bacterial and
synthetic)
CTB—2L21/GFP—2L21
Pag
CaF1~LcrV

Cholera toxin

Tetanus toxin

Canine parvovirus (CPV)
Anthrax protective antigen
Plague vaccine

Gene

Vaccine antigens

TrnI/trnA
TrnI/trnA
TrnI/trnA

TrnV/rps12/7

TrnI/trnA

Site of
integration

Prrn
Prrn
Prrn

Prrn

Prrn

Promoter

T7 gene 10a,
atpBb / TrbcL
PpsbA/TpsbA
PpsbA/TpsbA
PpsbA/TpsbA

ggagg/ TpsbA

5′/3′ Regulatory
elements

a

b

31.1%, 22.6%
4%–5%
14.8%

25% , 10%

4%

% TSP
expression
GM—1 ganglioside
binding assay
Positive systemic
immune response
Immune response
Macrophage lysis assay
ND

Functionality assay

Daniell, Veramandi 2004
Daniell 2004
Daniell 2003

Maliga 2003

Daniell 2001

Lab/year
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Gene

EG121
hST
MSI—99v
IGF—1
INFα 5
INFα 2B
hsa
IFN-g
Guy’s 13

Biopharmaceutical
proteins

Elastin-derived polymer
Human somatotropin

Antimicrobial peptide

Insulin-like growth factor
Interferon-α 5
Interferon-α 2b

Human serum albumin
Interferon-γ

Monoclonal antibodies

trnI/trnA

trnI/trnA
rbcL/accD

trnI/trnA
trnI/trnA
trnI/trnA

trnI/trnA

trnI/trnA
trnV/rps12/7

Site of
Integration

ggagg/ TpsbA

ggagga, psbAb/TpsbA
PpsbA/TpsbA

Prrna, PpsbAb
PpsbA
Prrn

PpsbA/ TpsbA
PpsbA/TpsbA
PpsbA/TpsbA

T7gene10/TpsbA
T7gene10a or psbAb/
Trps16
ggagg/TpsbA

5′/3′ Regulatory
elements

Prrn
Prrn
Prrn

Prrn

Prrn
Prrna, P psbAb

Promoter

ND

0.02%a, 11.1% b
6%

33%
ND
18.8%

21.5% – 43%

ND
7.0% a and 1.0% b

% TSP expression

Inverse temp. transition assay
Positive growth response of Nb2
cell line
Minimum inhibitory conc. (MIC)
of P. aeruginosa
ND
ND
Protection of HeLA cells against
cytopathic effects of EMC virus
ND
Protection of human lung carcinoma cells against infection by
EMC virus
ND

Functionality assay

Daniell 2001

Daniell 2003
Reddy 2003

Daniell 2002
Daniell 2002
Daniell 2002

Daniell 2001

Daniell 2000
Monsanto 2000

Lab, year
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